Drug Combo Nivolumab plus ipilimumab Has Best Survival Rates in Relapsed Mesothelioma

Drug Combo Nivolumab plus ipilimumab Has Best Survival Rates in Relapsed Mesothelioma

Malignant pleural mesothelioma is an aggressive cancer with limited therapeutic options. Pemetrexed plus platinum is often the first treatment option that clinicians turn to. There are now several options for second treatment therapy. This is useful in patients with relapsed mesothelioma. Yet some of these treatment therapies remain controversial. Several drugs were recently introduced to treat relapsed mesothelioma. A new study conducted a meta-analysis to check the efficacy of these drugs. After Chemotherapy, What Comes Next? Nivolumab alone or nivolumab plus ipilimumab provided significantly longer patient survival. In fact, treatment with nivolumab plus ipilimumab was found to have the best survival rates. Other treatments had a good survival rate compared with a placebo. These other treatments included tremelimumab, vorinostat, and chemotherapy … Continue reading Drug Combo Nivolumab plus ipilimumab Has Best Survival Rates in Relapsed Mesothelioma »

COVID-19 Pandemic Had Little Or No Impact On New Malignant Mesothelioma Diagnoses

COVID-19 Pandemic Had Little Or No Impact On New Malignant Mesothelioma Diagnoses

A new study published in Thoracic Cancer discussed the impact of COVID‐19 pandemic on new mesothelioma diagnoses in Italy. Malignant mesothelioma is a rare disease of great interest to the scientific community and to public health. This is due to its high lethality and its association with asbestos exposure. The timely diagnosis of mesothelioma is important. Although it may not change the prognosis of the disease, it can help in treatment strategies. It can also help in documenting previous exposure to asbestos. This can contribute to any request for compensation. New Study Shows Promising Results During the COVID-19 pandemic, there was a delay in the diagnosis of oncological diseases. This was because many departments were converted into COVID wards. And … Continue reading COVID-19 Pandemic Had Little Or No Impact On New Malignant Mesothelioma Diagnoses »

Hope for Mesothelioma Patients with Genetic Predisposition (Germline PVs) for Cancer

Mesothelioma Patients with Genetic Predisposition for Cancer are Candidates for Personalized Medicine

Malignant pleural mesothelioma is a tumor caused by asbestos exposure. Recently, the United States Food and Drug Administration approved immunotherapy treatment for mesothelioma. But the efficacy of available treatments is still limited. Researchers are still evaluating these new therapeutic approaches. They are also working to identify subgroups of patients who could benefit from precision medicine. Precision medicine uses information about a person’s tumor to find out how well a treatment is working. One of these groups could be represented by patients with an inherited cancer syndrome. These are caused by germline pathogenic variants (PVs) in DNA repair genes. A germline pathogenic variant is a gene variant (or mutation) that is passed from parent to child. These germline PVs are hereditary. … Continue reading Hope for Mesothelioma Patients with Genetic Predisposition (Germline PVs) for Cancer »

Understanding CAR T-Cell Therapy in Malignant Mesothelioma

Understanding CAR T-Cell Therapy in Malignant Pleural and Peritoneal Mesothelioma

One of the new therapies for mesothelioma is called antigen receptor T-cell therapy. It gives promise to malignant mesothelioma patients. This unique therapy has recently shown that it works in phase I clinical trials. A new report from French scientists details the current state of this therapy. This therapy has only been tested in a highly selected patient population. And it requires highly complex engineering. Yet, the treatment therapy shows promise. Adapting CAR T-Cell Therapy to Mesothelioma Malignant pleural and peritoneal mesothelioma are rare and aggressive cancers. They have had limited treatment options with moderate survival benefits. And all treatments have an impaired quality of life for a very long period. A chemotherapy drug combination known as cisplatin–pemetrexed has been … Continue reading Understanding CAR T-Cell Therapy in Malignant Mesothelioma »

Using CT Scans in Surgical Decision-Making in Peritoneal Mesothelioma

Using CT Scans in Surgical Decision-Making in Peritoneal Mesothelioma

Peritoneal mesothelioma is caused by asbestos. The peritoneum is the space in your abdomen that contains the intestines, the stomach, and the liver. The abdomen (peritoneum) is the second most common site of mesothelioma after the pleural (lungs and chest). Most doctors believe peritoneal mesothelioma is caused by the ingestion of asbestos fibers. Microscopic asbestos fibers become embedded in the abdomen (peritoneum). After about 20-50 years, these fibers can cause inflammation and mutations in the healthy mesothelial cells. These mutations may ultimately cause these cells to become cancerous. Thus, forming tumors in the peritoneum. Patients diagnosed with peritoneal mesothelioma may survive several or more years after diagnosis. There are long-term survivors, such as Paul Kraus. Using CT Scans to Avoid … Continue reading Using CT Scans in Surgical Decision-Making in Peritoneal Mesothelioma »

Mesothelioma Risk in Canadian Firefighters and Police

Mesothelioma Risk in Canadian Firefighters and Police

Firefighters and police usually work in high-stress, complex environments. And, these environments often have known and suspected hazardous and toxic exposures. A leading cause of mesothelioma is asbestos exposure. Asbestos is toxic and cancer-causing for human beings. Asbestos causes mesothelioma and other asbestos-related diseases. Canadian researchers published a new study in Occupational and Environmental Medicine. This new report characterizes cancer incidence among these occupations. Firefighters vs. Police The Canadian team used an Occupational Disease Surveillance System (ODSS) to identify workers. Then they compared compensation claims to the Ontario Cancer Registry. They found 36,267 people employed as firefighters or police in Ontario. In the final analysis, there were a total of 13,642 firefighters and 22,595 police. When compared with other workers, … Continue reading Mesothelioma Risk in Canadian Firefighters and Police »

Is Asbestos Fiber Type or Concentration More Important in Mesothelioma?

Is Asbestos Fiber Type or Concentration More Important in Mesothelioma?

Malignant pleural mesothelioma is strongly associated with occupational asbestos exposure. The total asbestos fiber concentration may be associated with an increased risk of mortality. Asbestos fiber type was not as important. A new study looked at different types and concentrations of asbestos fibers in the lung tissues of mesothelioma patients. The team investigated their effects on patient mortality. Asbestos Fiber Analyses A Finnish team of scientists identified 590 patients to study. All patients had malignant pleural mesothelioma and underwent pulmonary asbestos fiber analysis. A pulmonary asbestos fiber type analysis is a special clinical test. It extracts fibers and asbestos bodies from a patient’s lung tissue. Usually, this uses a digestion-and-concentration technique. The examination may even include electron diffraction and energy-dispersive … Continue reading Is Asbestos Fiber Type or Concentration More Important in Mesothelioma? »

Understanding the New Multimodality Prognostic Score (MMPS) in Mesothelioma

Understanding the New Multimodality Prognostic Score (MMPS) in Mesothelioma

The Multimodality Prognostic Score (MMPS) is a new tool for evidence-based mesothelioma treatment. It has given clinicians and surgeons a new guideline in multimodality treatment. The treatment options for mesothelioma are many. Often, one treatment alone cannot control cancer so many treatment types are required. Multimodal therapy can be tailored to each patient’s case. The Multimodality Prognostic Score (MMPS) has an update. It is a tool in the clinician’s toolbox for outlining a treatment plan. Surgical Options Surgery is a common treatment option for malignant pleural mesothelioma. There are two surgeries that are most common. The first is pleurectomy and decortication (P/D) surgery. The second is an extrapleural pneumonectomy (EPP). Pleurectomy and decortication surgery (P/D) is a common pleural mesothelioma … Continue reading Understanding the New Multimodality Prognostic Score (MMPS) in Mesothelioma »

Treatment Combination for Younger Pre-Treated Mesothelioma Patients

Treatment Combination for Younger Pre-Treated Mesothelioma Patients

There are many systemic therapies recommended for mesothelioma patients. Different therapies may work best for different patient populations. Different therapies may work better for older versus younger patients. Or, patients who have received treatment before. An international team of clinicians published a new study on this topic. They found a treatment strategy that works best for younger pre-treated patients. The Young (65 years or younger) and Pre-Treated Patient Mesothelioma patients who have received treatment once before, are often called “pre-treated.” Clinicians often have more personalized data available for these patients. This affects the clinician’s treatment strategy. A new study compared the data from nine different mesothelioma clinical trials. These clinical trials spanned standard and experimental treatment options. The results are … Continue reading Treatment Combination for Younger Pre-Treated Mesothelioma Patients »

A New Prognostic Signature Discovered for Malignant Pleural Mesothelioma

New Prognostic Signature Discovered for Malignant Pleural Mesothelioma

Immune-related genes play an important role in malignant pleural mesothelioma prognosis. They can affect the tumor immune microenvironment and affect tumor prognosis. Immune-related genes can be used to predict the course of a disease or patient outcomes. These genes are often called a genetic prognostic signature. Chinese surgeons recently discovered a prognostic signature for malignant pleural mesothelioma patients. Constructing a Prognostic Signature with 5 Immune-Related Genes Genes play an important role in the development and progression of cancers like mesothelioma. The Chinese researchers started by searching for other studies on mesothelioma prognosis and genes. Researchers used data from the Cancer Genome Atlas to construct the prediction signature. Patients were divided into high-risk and low-risk groups. They also used this data … Continue reading A New Prognostic Signature Discovered for Malignant Pleural Mesothelioma »

Get your free copy of
“Surviving Mesothelioma” Today!